The breast cancer screening debate: closing a chapter?
A partir d'une revue de la littérature, cette méta-analyse de 11 essais randomisés évalue la réduction de la mortalité par cancer du sein et le surdiagnostic associés au programme britannique de dépistage du cancer du sein
Fierce debates about the benefits and harms of breast cancer screening have been played out in pages of The Lancet, many other journals, and the mainstream media for a decade or more. Many researchers believe that the benefits of screening, in terms of reduced breast cancer mortality, outweigh the harms (eg, overdiagnosis). Others think the opposite. These polarised discussions are likely to have caused confusion among women about attending for breast screening. In response to this debate, in October, 2011, England's National Cancer Director, Mike Richards, initiated an independent review into breast cancer screening. This assessment is now complete and is summarised in a Review published in The Lancet. It should begin to lay the benefits versus harm controversy to rest...
The Lancet , éditorial en libre accès, 2011